Catalog No.
Product Name
Application
Product Information
Citations
-
Piperazine
2-BZP is a piperazine compound that functions as a central nervous system stimulant by targeting serotonin and dopamine receptors. Its primary biological activity includes modulation of neurotransmitter release, making it useful in research related to neuropharmacology and behavioral studies. 2-BZP serves as a valuable tool for elucidating the mechanisms of psychostimulant effects and exploring potential therapeutic applications. -
Piperazine
1-(3-Chloro-4-fluorophenyl)piperazine hydrochloride is a piperazine derivative that acts as a potent and selective modulator of various neurotransmitter systems. This compound is primarily utilized in neuroscience research to investigate its effects on serotonin and dopamine receptors, contributing to the understanding of mood disorders and psychotropic drug action. Its unique chemical structure makes it valuable for studies related to pharmacology and medicinal chemistry. -
Drug Impurity
Paliperidone impurity 3 is a known impurity of the antipsychotic agent Paliperidone, which primarily targets dopamine receptors. This compound is utilized in pharmaceutical research for quality control and to assess the purity of Paliperidone formulations. It serves as a crucial reference standard in the development and validation of analytical methods, ensuring compliance with regulatory standards in drug production. -
Neuroleptic Agent
Fenaperone hydrochloride is a neuroleptic agent that primarily targets dopamine receptors in the central nervous system. It exhibits antipsychotic properties, making it relevant for research in neurological disorders and psychiatric conditions. Its mechanism includes modulation of neurotransmitter activity, contributing to its potential therapeutic effects in various mental health applications. -
Drug Derivative
Methiomeprazine is a drug derivative primarily targeting the dopaminergic system. It exhibits significant antipsychotic and sedative properties, making it valuable in the treatment of various psychiatric disorders. Methiomeprazine is commonly used in research related to neuropharmacology and the exploration of dopamine receptor interactions. Its efficacy in managing behavioral symptoms also positions it as a candidate for studies on mental health therapies. -
Biochemical Assay Reagent
Duoperone is a neuroleptic agent that acts primarily by antagonizing dopamine receptors. This compound exhibits significant antiemetic properties in various animal models, making it valuable for studies related to nausea and psychotic disorders. Its applications extend to biochemical assays that investigate neurotransmitter dynamics and the pharmacological evaluation of antipsychotic drugs. -
Drug Impurity
Pramipexole impurity 1 (2-N-Propyl pramipexole) is a chemical impurity associated with the drug Pramipexole, which targets dopamine receptors. This impurity is essential for quality control and validation studies in pharmaceutical research, ensuring the purity and safety of drug formulations. It serves as a reference compound in analytical chemistry and can facilitate the investigation of drug metabolism and pharmacokinetics. -
Drug Impurity
Ropinirole impurity 2 is a chemical impurity associated with the synthesis of Ropinirole, a dopamine receptor agonist. This compound can be utilized for analytical purposes in the assessment of drug purity and quality control in pharmaceutical research. Its presence is significant for the evaluation of Ropinirole formulations and may impact the overall efficacy and safety profile of the drug. -
Drug Derivative
SKF 83692 is a potent derivative that primarily targets dopamine receptors, specifically D1-like receptors. This compound exhibits notable biological activity in modulating dopaminergic signaling, making it valuable for research in neuropharmacology and the study of dopamine-related disorders. SKF 83692 serves as an important tool for investigating receptor pharmacology and the potential therapeutic effects of dopamine modulation in various neurological conditions. -
Benzofuran
5-EAPB hydrochloride is a benzofuran derivative that acts primarily as a serotonin and dopamine receptor modulator. This compound is known for its psychoactive properties and has been used in neurological research to explore the mechanisms of mood regulation and cognitive function. Its ability to enhance serotonergic transmission makes it a valuable tool for studying various neuropharmacological applications. -
Drug Derivative
N-Acetyl-3,4-MDMC is a drug derivative structurally related to 3,4-methylenedioxymethcathinone. This compound has been investigated for its psychoactive properties and potential interactions with monoamine transporters, particularly serotonin and dopamine receptors. Research applications include studies on its effects on neural activity and behavioral responses in various models of neurotransmission. -
Drug Impurity
Ropinirole impurity 5 is a chemical impurity associated with Ropinirole, a dopamine agonist primarily targeting the D2 and D3 dopamine receptors. This impurity is important for analytical and quality control purposes in pharmaceutical research and development. Its identification and quantification are crucial for ensuring the purity and safety of Ropinirole formulations. -
Drug Impurity
Ropinirole impurity 1 is a structural impurity derived from Ropinirole, a selective dopamine agonist primarily targeting D2 dopamine receptors. This reagent is crucial for analytical and quality control applications, serving as a reference standard for assessing the purity and quality of Ropinirole formulations. Its characterization aids in the understanding of processing variability and ensures compliance with regulatory standards in pharmaceutical development. -
Intermediate
2-Benzylaniline is an intermediate compound that serves as a precursor in the synthesis of Compound 15. This derivative exhibits affinity for the D3 dopamine receptor, with a Ki value of 4654 nM. 2-Benzylaniline is valuable in research related to mental disorders, enabling the exploration of therapeutic targets within neuropharmacology. -
Drug Impurity
Brexpiprazole impurity 1 is a chemical impurity related to the atypical antipsychotic Brexpiprazole, which primarily targets serotonin and dopamine receptors. This impurity can be utilized in the assessment of drug quality and to investigate the stability and degradation pathways of Brexpiprazole. Its presence may influence the pharmacological profile and safety evaluations in related research applications. -
Drug Derivative
Bmapn is a drug derivative with impactful interactions on dopamine signaling pathways. It exhibits rewarding and reinforcing properties by decreasing dopamine transporter levels and enhancing dopamine receptor D2 gene expression specifically in the striatum. This compound is valuable for research applications studying addiction, neuropharmacology, and the modulation of dopaminergic systems. -
Stable Isotope
Boc-Leu-OH·H2O-13C is a stable isotope-labeled derivative of N-Boc-L-leucine, featuring a carbon-13 (13C) label. This amino acid derivative, protected with a Boc group, serves as an essential building block for the synthesis of peptides, such as L-prolyl-L-leucyl-glycinamide, which exhibit modulatory activity on dopamine receptors. It is valuable for applications in peptide research, metabolic studies, and tracer experiments utilizing stable isotopes. -
Racemate of NNC 55-0396
(Rac)-NNC 55-0396 is a racemic mixture that targets the dopamine D2 receptor. This compound is of significant interest in neurological research due to its potential role in modulating dopaminergic signaling pathways. It is commonly utilized in studies investigating the pharmacological effects of dopamine receptor antagonists in various neurological disorders. -
DRD4 Antagonist
PD 168568 is a potent and orally active antagonist of the dopamine receptor D4 (DRD4), featuring an isoindolinone structure. It demonstrates strong selectivity for the D4 receptor over D2 and D3 receptors, with Ki values of 8.8 nM, 1842 nM, and 2682 nM, respectively. This compound is valuable for research applications focusing on glioblastoma (GBM), providing insights into the role of DRD4 in tumor biology. -
D3R Antagonist
PF-04363467 is a selective antagonist of the dopamine D3 receptor (D3R). It demonstrates dose-dependent modulation of the electroencephalogram (EEG) profile in freely moving rats, highlighting its potential to influence neural activity. This compound effectively reduces opioid drug-seeking behavior while minimizing undesired side effects associated with D2 receptor antagonism. PF-04363467 is valuable for research into addiction, cognitive disorders, and mental illness. -
Dopamine Autoreceptor Agonist
PD 128483 is a selective agonist of the dopamine autoreceptor, primarily engaging the D2 receptor subtype. This compound is instrumental in research related to neurological diseases, facilitating studies on dopamine signaling and its implications in disorders such as schizophrenia and Parkinson’s disease. Its ability to modulate dopamine release provides valuable insights into neuropharmacology and therapeutic interventions. -
Haloperidol Analogue
UCSF34 is a Haloperidol analogue that selectively binds to the human D2L receptor, exhibiting an estimated pKi of 7.49. This compound is significant for its potential applications in schizophrenia research, facilitating the investigation of dopamine receptor modulation and related therapeutic strategies. -
Dopamine Receptor Antagonist
Seridopidine is a potent dopamine receptor antagonist that primarily targets D2 and D3 receptors. It exhibits significant antipsychotic activity, making it valuable for research in neurological and psychiatric disorders. This compound is useful in studies investigating the roles of dopamine in the central nervous system, particularly in understanding mechanisms underlying schizophrenia and related conditions. -
Dopamine D2 Receptor Agonist
U 101958 is a potent full agonist of the dopamine D4 receptor, exhibiting a pEC50 of 8.7 in HEK293 cells expressing the D4 receptor. This compound demonstrates significant biological activity and is valuable for research in neuropharmacology, particularly in studies examining the role of dopamine signaling in psychiatric disorders. Its selectivity for the D4 receptor can aid in the exploration of D4-mediated effects in various biological systems. -
Dopamine D1 Receptor PAM
LY3154885 is an orally active positive allosteric modulator (PAM) targeting the dopamine D1 receptor. This compound enhances receptor activity, facilitating increased dopaminergic signaling. Its favorable drug-drug interaction profile makes it a valuable tool for research into dopamine-related pathways and potential therapeutic applications in neuropsychiatric disorders. -
Dopamine Receptor
Quinagolide is a non-ergot dopamine D(2) receptor agonist that enhances dopamine activity. It is primarily utilized in the modulation of endocrine function, particularly in the suppression of hyperprolactinemia and its associated clinical symptoms. Quinagolide's significant biological activity makes it a valuable reagent for research in endocrine disorders and drug development, facilitating the study of dopamine's role in various physiological processes. -
D3R Ligand
D3R ligand 1 is a potent and selective antagonist targeting the dopamine receptor D3R, with a Ki value of 66 nM. Utilizing a THPB template, this compound effectively inhibits both G-protein- and β-arrestin-mediated signaling pathways. D3R ligand 1 is valuable for researchers investigating dopamine receptor signaling and its implications in neuropharmacology. -
D1 Receptor Agonist
A-77636 is a potent and selective orally active agonist of the dopamine D1 receptor, demonstrating a pEC50 of 8.13 and an EC50 of 1.1 nM. It exhibits a high affinity for the dopamine D1 receptor with a pKi value of 7.40 ± 0.09 (Ki = 39.8 nM). Due to its pharmacological profile, A-77636 is primarily utilized in research related to Parkinson's disease and other dopamine-related disorders. -
Dopamine D-1 Receptor Antagonist
A-69024 is a selective antagonist of the dopamine D-1 receptor, demonstrating a Ki value of 12.6 nM for D-1 and a significantly higher Ki value of 1290 nM for the D-2 receptor. This compound's specificity enables researchers to investigate the role of dopamine D-1 receptor modulation in various neurological and psychiatric disorders. A-69024 is valuable for studies examining dopamine-related pathways and potential therapeutic approaches. -
D2R Agonist
UNC9975 is a D2 receptor (D2R) agonist that demonstrates signaling bias through β-arrestin-mediated pathways while also acting as an antagonist of Gi-regulated cAMP production and a partial agonist for D2R/β-arrestin-2 interactions. This compound is valuable for research in antipsychotic drug development, facilitating the exploration of novel therapeutic approaches targeting dopaminergic signaling. -
Noncatechol Agonist
Noncatechol agonist-1 is a potent noncatechol agonist primarily targeting the dopamine D1 receptor (D1R). It demonstrates full efficacy in activating both the D1R-G protein and D1R-β-arrestin2 pathways, with pEC50 values of 8.41 for D1R-mediated cAMP production and 7.7 for β-arrestin2 recruitment. This compound is valuable for research applications investigating dopamine signaling and its implications in neurobiology and pharmacology. -
Dopamine D1 Receptor Agonist
Zelandopam free base is a specific agonist of the dopamine D1 receptor, demonstrating notable renal vasodilatory effects. This compound is effective in mitigating acute renal failure induced by Cisplatin, making it a valuable tool for research investigating renal protection and dopamine receptor signaling. Its oral bioactivity further enhances its utility in pharmacological studies related to renal function and neurotransmitter interactions. -
Dopamine D1 Receptor Agonist
SKF 38393 is a selective agonist of the dopamine D1 receptor that activates the cAMP signaling pathway, enhancing dopamine release in the developing rat striatum. This compound has been shown to inhibit the proliferation of MCF-7 breast cancer cells with an IC50 of 0.1 μM. SKF 38393 is instrumental in research focused on neurodevelopmental disorders, dopamine-related diseases such as Parkinson's, and cancer biology. -
D3 Dopamine Receptor Agonist
7-Hydroxy-DPAT is a selective agonist of the D3 dopamine receptor, known for its ability to modulate locomotor behavior and influence dopamine metabolism in the brain. This compound demonstrates significant pharmacological activity that can be utilized in research focused on neurological diseases and disorders. Its selectivity for the D3 receptor makes it a valuable tool for studies investigating dopamine-related pathways and their implications in various neurological conditions. -
D3R Agonist
OS-3-106 is a potent and selective agonist of the dopamine D3 receptor (D3R), demonstrating a high binding affinity with a Ki value of 0.2 nM. This compound serves as a valuable tool in the study of D3R-mediated pathways, particularly in the context of psychoactive substance addiction research. Its specificity and efficacy make it suitable for exploring mechanisms underlying dopamine signaling and addiction-related behaviors. -
D1 Receptor Agonist
SKF83822 hydrobromide is a potent agonist of the dopamine D1 receptor, primarily engaging Gs/olf signaling pathways to activate adenylyl cyclase. It is effective in stimulating intracellular cAMP production, making it a valuable tool for research in neuropharmacology and the study of dopamine-related disorders. Its selectivity for D1 receptors over PLC-coupled D1-like receptors underscores its utility in elucidating D1-mediated signaling processes. -
Dopamine D2 Receptor Agonist
PF-00217830 is a selective agonist of the dopamine D2 receptor, demonstrating substantial efficacy in modulating dopaminergic signaling. It has been shown to inhibit spontaneous locomotor activity as well as reduce 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rodent models. This compound is valuable for studying the role of dopamine in neuropharmacology and assessing potential therapeutic strategies for disorders associated with dopamine dysregulation. -
Dopamine D2 Receptor Antagonist
Dopamine D2 receptor antagonist-3 is a selective antagonist of the dopamine D2 receptor, displaying a pIC50 of 5.52. This compound demonstrates antipsychotic effects, evidenced by its ability to reduce apomorphine-induced agitation in rat models. It is a valuable tool for research into psychiatric and neurological disorders, facilitating the study of dopaminergic signaling pathways and potential therapeutic interventions. -
D4 dopamine receptor antagonist
L-750667 triHydrochloride is a selective antagonist of the D4 dopamine receptor, exhibiting a Ki value of 0.51 nM. Its radiolabeled derivative, [125I]L-750667, demonstrates a Kd of 0.16 nM for D4 receptor binding. This compound is capable of reversing dopamine-induced inhibition of cAMP accumulation, making it a valuable tool for investigating the distribution and function of D4 dopamine receptors in the central nervous system. L-750667 triHydrochloride has significant applications in neuroscience and psychiatry research. -
Dopamine Receptor Inhibitor
SV 293 is a selective antagonist that primarily targets dopamine D2 receptors with a binding affinity that is 100-fold greater than that of D3 and D4 receptor subtypes. This compound exhibits neutral antagonist activity and effectively blocks the effects of the full agonist quinpirole in forskolin-dependent adenylate cyclase inhibition assays and electrophysiological assays. SV 293 serves as a valuable pharmacological tool for investigating the role of D2-like receptor subtypes in dopamine-related pathways associated with neurological, neuropsychiatric, and movement disorders. -
Dopamine Receptor
LY 171859 is a selective D2 receptor agonist that also displays notable reductase activity. This compound demonstrates enzymatic function within the cytoplasm of various tissues, including liver, lung, and kidney, and exhibits significant reductase activity in both rat and human blood. The reduction process mediated by LY 171859 is NADPH-dependent, with an apparent Km of 14.8 μM, and specifically incorporates the A-side hydrogen of NADPH into the reaction product. Additionally, this compound's enzymatic activity is sensitive to inhibition by cyanide and thiol reagents, making it a useful tool for studying dopamine receptor signaling and associated metabolic pathways. -
MOR Agonist
MOR agonist-2 is a potent agonist of the mu-opioid receptor (MOR) with a Ki value of 564 nM, and it acts as an antagonist at the dopamine D3 receptor (D3R) with a Ki of 7.26 nM. This compound exhibits analgesic properties through its partial agonism at MOR, making it a valuable tool for research in pain management. Additionally, its D3R antagonism may help mitigate opioid misuse liability, offering potential therapeutic benefits in addiction studies. -
Antioxidant/Antitumor Agent
Vanicoside E is an antioxidant and antitumor agent that targets L-Tyrosine and L-DOPA, demonstrating inhibitory activity with IC50 values of 45.23 μM and 189.96 μM, respectively. This compound is utilized in research focused on oxidative stress and tumor biology, making it valuable in studies aimed at understanding cancer progression and developing therapeutic strategies. Its properties support investigations into the modulation of key biochemical pathways relevant to tumor growth and survival. -
Dopamine D2 Receptor Antagonist
BRL 34778 is a highly selective dopamine D2 receptor antagonist with a Ki value of 2.14 nM, demonstrating significant potency in receptor inhibition. It exhibits antipsychotic properties while minimizing extrapyramidal side effects and sedation. This compound is valuable for investigating neurological disorders, particularly schizophrenia, and contributes to research focused on the modulation of dopaminergic pathways in the brain. -
Dopamine D1 Receptor Agonist
Zelandopam anhydrous is a selective agonist of the dopamine D1 receptor, exhibiting potent renal vasodilatory effects. This compound demonstrates significant potential in alleviating acute renal failure induced by Cisplatin. It is valuable for research in nephrology and may aid in exploring therapeutic approaches for renal pathologies. -
Dopamine Antagonist
Isoremoxipride is a dopamine antagonist that selectively targets the dopamine D2 receptor. This 3-methoxy isomer demonstrates significant affinity for the receptor, making it a valuable tool for investigating dopamine-related pathways. Its research applications include studies on neuropsychiatric disorders and the role of dopamine in various neurological conditions. -
D4R Antagonist
D4R antagonist-1 is a selective antagonist of the dopamine D4 receptor (D4R) with an IC50 of 6.87 µM. This compound exhibits significant potential for use in research related to neurological disorders, including Parkinson's disease. Its ability to modulate D4R activity makes it a valuable tool for investigating the role of dopamine signaling in various physiological and pathological processes. -
D2R Agonist
rel-Quinpirole dihydrochloride is a selective dopamine D2 receptor agonist that acts primarily on the D2R target. This compound exhibits significant biological activity in modulating dopamine signaling pathways and is utilized in research applications related to neurological diseases, including Parkinson's disease and schizophrenia. Its use can facilitate the investigation of dopaminergic functions and the development of potential therapeutic strategies. -
Dopamine Autoreceptor Antagonist
AJ-76, classified as a dopamine autoreceptor antagonist, plays a crucial role in modulating dopamine levels in the brain. Research shows that AJ-76 enhances the synthesis and turnover of dopamine while exhibiting minimal influence on serotonin and norepinephrine activity. Additionally, AJ-76 effectively counteracts the sedative effects associated with low-dose apomorphine and demonstrates a modest antagonistic effect at postsynaptic dopamine receptors, making it a valuable tool for research in neuropharmacology and the study of dopamine-related disorders. -
Dopamine Agonist
Lergotrile is a potent, orally active dopamine agonist that functions primarily as a prolactin secretion inhibitor. It exerts its biological activity by activating adenohypophyseal dopamine receptors, leading to the inhibition of prolactin release from the pituitary gland. This compound holds potential for research applications related to Parkinson's disease and other dopaminergic disorders.
